Patients who relapsed were not different from those in long-term remission with regard to PRL levels at diagnosis, treatment duration (p = 0.074), cumulative CBG dose (p = 0.223), previous use of other dopamine agonists, and frequency of adenoma disappearance before withdrawal. The gene discussed is PRL; the disease is adenoma.